



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Adrian BOT *et al.*

Appln. No.: 09/919,477

Filed: July 30, 2001

For: **Novel Methods and Compositions to  
Upregulate, Redirect or Limit Immune  
Responses to Peptides, Proteins and Other  
Bioactive Compounds and Vectors  
Expressing the Same**

Art Unit: 1614

Examiner: To Be Assigned

Atty. Docket: 17945.014

Confirmation No.: 3914

**Response to Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures**

Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Notice to Comply With Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 15,  
2002, Applicants submit the following documents for appropriate action by the U.S. Patent and  
Trademark Office:

1. Copy of the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Sequence listing in computer readable form (CRF) for the above referenced  
application, on a floppy disk;
3. A Statement Regarding Sequence Submission; and,
4. A paper copy of the sequence listing.

A paper copy of the Sequence Listing and a computer readable form (CRF) of the  
sequence listing on floppy diskette, containing the file named SequenceListing.txt, which is 666  
bytes in size (measured in MS-DOS), and which was created on December 2, 2002, are herein  
incorporated by reference.

***Remarks***

The Sequence Listing has been formatted to comply with current 37 C.F.R. § 1.821 *et seq.* No new matter enters by this Response.

Respectfully submitted,


A handwritten signature in black ink, appearing to read "Milan M. Vinnola". The signature is fluid and cursive, with the first name "Milan" being more prominent.

David R. Marsh (Reg. No. 41,408)

Milan M. Vinnola (Reg. No. 45,979)

Date: December 13, 2002

ARNOLD & PORTER  
555 Twelfth Street, N.W.  
Washington, D.C. 20004-1206  
(202) 942-5000 telephone  
(202) 942-5999 facsimile



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/919,477	07/30/2001	Adrian Bot	ALLIA.228A

**CONFIRMATION NO. 3914**

Michael J. Rafa Esq.  
INHALE THERAPEUTIC SYSTEMS, INC.  
150 INDUSTRIAL ROAD  
SAN CARLOS, CA 94070-6256

**FORMALITIES LETTER**



\*OC00000008952471\*

Date Mailed: 10/15/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*Ryan*

Customer Service Center

Initial Patent Examination Division (703) 308-1202


PART 2 - COPY TO BE RETURNED WITH RESPONSE

20A  
G  
0320  
Box Seg

---

# ARNOLD & PORTER

202.942.5000  
202.942.5999 Fax  
555 Twelfth Street, NW  
Washington, DC 20004-1206



December 13, 2002

Commissioner for Patents  
Washington, DC 20231

Re: U.S. Application No. 09/919,477  
Filed: July 30, 2001  
Title: **Novel Methods and Compositions to Upregulate,  
Redirect or Limit Immune Responses to Peptides,  
Proteins and Other Bioactive Compounds and Vectors  
Expressing the Same**  
Inventors: Adrian BOT *et al.*  
Atty. Docket: 17945.014

Sir:

The following documents are forwarded herewith for appropriate action by the U.S.  
Patent and Trademark Office (PTO):

1. a Response to Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. a Copy of the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
3. a Sequence Listing in Computer Readable Form (CRF);
4. a Statement Regarding Sequence Submission;
5. a paper copy of the sequence listing; and
6. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to  
our courier.

Applicants do not believe any fees are due in conjunction with this filing. However, if  
any fees under 37 C.F.R. §§ 1.16 or 1.17 are required in the present application, including any  
fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to

---

# ARNOLD & PORTER

---

Commissioner for Patents  
Atty. Docket: 17945.014  
Adrian BOT *et al.*  
Page 2

Arnold & Porter Deposit Account No. 50-2387, referencing matter number 17945.014. A duplicate copy of this letter is enclosed.

Respectfully submitted,

A handwritten signature in cursive script, reading "Milan M Vinnola".

David R. Marsh (Reg. No. 41,408)  
Milan M. Vinnola (Reg. No. 45,979)

Attachments